found that lower pre-treatment C-reactive protein/albumin ratio (CRP/Alb) and carcinoembryonic antigen/albumin ratio (CEA/Alb) were closely associated with higher pathological response rates in patients undergoing neoadjuvant therapy for gastric cancer. The gene discussed is CEACAM5; the disease is gastric cancer.